Cartesian Therapeutics (RNAC) Expected to Announce Earnings on Thursday

Cartesian Therapeutics (NASDAQ:RNAC) is projected to release its results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($1.02) per share and revenue of $0.16 million for the quarter.

Cartesian Therapeutics (NASDAQ:RNAC) last issued its earnings results on Thursday, August 6th. The company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $1.34. On average, analysts expect Cartesian Therapeutics to post ($3.15) EPS for the current fiscal year and ($4.14) EPS for the next fiscal year.

Cartesian Therapeutics Stock Performance

RNAC opened at $6.41 on Wednesday. The company’s 50-day simple moving average is $7.59 and its two-hundred day simple moving average is $7.65. Cartesian Therapeutics has a 52-week low of $5.60 and a 52-week high of $11.00.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on RNAC. Zacks Research upgraded shares of Cartesian Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Needham & Company LLC restated a “buy” rating and set a $40.00 price objective on shares of Cartesian Therapeutics in a research report on Tuesday, September 29th. Wedbush restated an “outperform” rating and issued a $38.00 target price on shares of Cartesian Therapeutics in a report on Tuesday, August 18th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Cartesian Therapeutics in a research report on Wednesday, September 30th. Finally, Wall Street Zen upgraded shares of Cartesian Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.60.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc (NASDAQ: RNAC) is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. The company’s platform is designed to program a patient’s own immune cells with messenger RNA, enabling the development of cell therapies that are intended to provide targeted treatment without permanent genetic modification.

Cartesian’s lead product candidate is Descartes-08, an autologous CAR T-cell therapy that targets B-cell maturation antigen (BCMA).